Tandem Diabetes Care Q3 2026 Results: Net Loss of $7.08M, Loss Narrows
Tandem Diabetes Care reported sales of $283.7 million for the third quarter of 2026, a 14% increase year-over-year, while significantly narrowing its quarterly net loss to $7.1 million from $21.2 million in 2025. The company strengthened its balance sheet by issuing convertible senior notes due 2032, contributing to a total asset base of $1.16 billion as of September 30, 2026.
- Key figure
- Net loss $7.08M